Aplos Medical

Executive Summary

Aplos Medical is a San Diego-based private medical device company focused on developing the Omega PF™, an implantable device for treating gastroesophageal reflux disease (GERD). Founded in 2018, the company aims to provide a practical, effective, and safe alternative to current treatment options, such as medication and surgical fundoplication. The Omega PF is designed to be implanted via a minimally invasive procedure, restoring the function of the lower esophageal sphincter. Aplos Medical has received regulatory approval for its device, positioning it to address the significant unmet need in the GERD market, which affects millions of patients worldwide. The company is now focusing on commercialization and market penetration, with a strategy to engage key opinion leaders and establish reimbursement. With its innovative approach and approved status, Aplos Medical is poised to capture a share of the growing GERD treatment market, estimated at over $10 billion annually.

Upcoming Catalysts (preview)

• Q2 2026First commercial sales and market launch80% success
• Q4 2026Publication of pivotal clinical trial results75% success
• TBDStrategic partnership or distribution agreement60% success